TABLE 1.
Characteristics of 576 Dutch IBD patients included in a prospective multicenter surveillance cohort study.
| Characteristic | Total cohort n = 576 | Ever smokers n = 275 | Never smokers n = 273 | Missing data (n) |
|---|---|---|---|---|
| Male sex, n (%) | 289 (50) | 129 (47) | 147 (54) | |
| Age (y), median (IQI) | 50 (39–58) | 54 (44–61) | 45 (34–53) | |
| IBD disease duration (y), median (IQI) | 18 (11–26) | 18 (13–27) | 17 (11–25) | 2 |
| IBD type, n (%) | ||||
| UC/IBD‐U | 316 | 145 (53) | 155 (57) | |
| CD | 260 | 130 (47) | 118 (43) | |
| Endoscopic disease extent, n (%) | 29 | |||
| Limited (E2 a /<50%) | 159 (28) | 84 (31) | 72 (26) | |
| Extensive (E3 a />50%) | 388 (67) | 177 (64) | 189 (69) | |
| Histologic disease extent, n (%) | 89 | |||
| E2 a /<50% | 81 (14) | 41 (15) | 40 (15) | |
| E3 a />50% | 406 (70) | 185 (67) | 198 (73) | |
| PSC, n (%) | 49 (9) | 11 (4) | 35 (13) | |
| Prior or index CRN (IND or LGD), n (%) | 134 (23) | 83 (30) | 46 (17) | |
| Surveillance history, n (%) | 410 (71) | 195 (71) | 197 (72) | |
| Positive family history of CRC, n (%) | 169 (29) | 95 (35) | 73 (27) | 33 |
| First degree relative | 78 (14) | 45 (16) | 33 (12) | |
| Smoking status, n (%) | 28 | |||
| Current | 72 (13) | 72 (26) | ‐ | |
| Quit | 203 (35) | 203 (74) | ‐ | |
| Never | 273 (47) | ‐ | 273 (100) | |
| Pack‐years, median (IQI) | 0 (0–8) | 9 (4–20) | ‐ | 50 |
| Current medication, n (%) | ||||
| 5‐ASA | 322 (56) | 149 (54) | 157 (58) | 1 |
| Thiopurine | 205 (36) | 84 (31) | 109 (40) | 1 |
| MTX | 27 (5) | 10 (4) | 15 (5) | 1 |
| Biological | 128 (22) | 64 (23) | 57 (21) | 1 |
| Previous medication use, n (%) | ||||
| 5‐ASA | 486 (84) | 231 (84) | 238 (87) | 9 |
| MTX or thiopurines | 354 (61) | 160 (58) | 175 (64) | 9 |
| Biological | 159 (28) | 73 (27) | 75 (27) | 11 |
| Risk category b , n (%) | 14 | |||
| High | 143 (25) | 72 (26) | 68 (25) | |
| Intermediate | 283 (49) | 130 (47) | 136 (50) | |
| Low | 136 (24) | 65 (24) | 64 (23) | |
Abbreviations: 5‐ASA, 5‐aminosalicylic acid; CD, Crohn’s disease; CRC, colorectal carcinoma; IBD‐U, inflammatory bowel disease unclassified; IND, indefinite for dysplasia; IQI, interquartile interval; LGD, low‐grade dysplasia; MTX, methotrexate; PSC, primary sclerosing cholangitis; UC, ulcerative colitis; y, years.
According to the Montreal classification. E2, left‐sided disease; E3, extensive disease.
According to the Dutch IBD surveillance guideline, high‐risk category: PSC, stricture (UC), prior dysplasia in <5 years, first‐degree relative with CRC (age <50 years); intermediate risk category: post‐inflammatory polyps, first‐degree relative with CRC (age >50 years), chronic disease activity, extensive disease; or low‐risk category in case of left‐sided UC or CD with <50% of colonic involvement.